IFNG and neoplasm: have developed an mRNA vaccine targeting neoantigens in MUC16 in breast and ovarian cancers, combined with CD40L and MHC-I targeting domains to enhance dendritic cell antigen presentation efficacy, with computational models predicting that this vaccine could activate IFN-γ and CD8+ T cells, playing a key role in tumor immunotherapy (171).